GlaukosGKOS
About: Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Employees: 907
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
104% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 26
38% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 90
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
10% more funds holding
Funds holding: 283 [Q2] → 310 (+27) [Q3]
7% more capital invested
Capital invested by funds: $6.63B [Q2] → $7.08B (+$447M) [Q3]
3.39% less ownership
Funds ownership: 111.26% [Q2] → 107.86% (-3.39%) [Q3]
30% less call options, than puts
Call options by funds: $19.5M | Put options by funds: $27.8M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
JP Morgan Allen Gong 70% 1-year accuracy 7 / 10 met price target | 5%upside $145 | Overweight Maintained | 5 Nov 2024 |
Wells Fargo Larry Biegelsen 60% 1-year accuracy 25 / 42 met price target | 5%upside $145 | Overweight Maintained | 5 Nov 2024 |
Truist Securities Richard Newitter 66% 1-year accuracy 31 / 47 met price target | 10%upside $152 | Buy Maintained | 14 Oct 2024 |
Stifel Thomas Stephan 35% 1-year accuracy 6 / 17 met price target | 5%upside $145 | Buy Maintained | 3 Sept 2024 |
BTIG Ryan Zimmerman 66% 1-year accuracy 29 / 44 met price target | 0%upside $139 | Buy Maintained | 28 Aug 2024 |
Financial journalist opinion
Based on 8 articles about GKOS published over the past 30 days
